Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL28273879 | 0.92 | EGFR (0.65) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL28821495 | 0.92 | EGFR (0.65) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL29490398 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL22833783 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL5920 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL29356169 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| SCHEMBL3196932 | 0.86 | EGFR (0.95) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL5579413 | 0.86 | EGFR (0.95) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL1119374 | 0.86 | EGFR (0.95) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL21055790 | 0.86 | EGFR (0.95) | EGFRPIK3CDPIK3CATDO2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101987847-B | Novel heterocyclic NF-kB inhibitors | 4SC AG | 2012-10-10 | — | — | CN | disclosed |
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8106048-B2 | protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester | 4SC AG (DE) | 2012-01-31 | — | — | US | disclosed |
| CN-101031567-B | Novel heterocyclic NF-kB inhibitors | 4SC Corp.,Ltd. (DE) | 2011-12-21 | — | — | CN | disclosed |
| EP-2343293-A1 | NOVEL PIPERIDIN-4-YL-THIAZOLE-CARBOXAMIDE ANALOGUES AS INHIBITORS OF T-CELL PROLIFERATION AND USES THEREOF | 4SC AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2042504-B1 | Fused azole-pyrimidine derivatives | BAYER SCHERING PHARMA AG (DE) | 2011-06-01 | — | — | EP | disclosed |
| CN-101987847-A | Novel heterocyclic NF-kB inhibitors | 4SC AG | 2011-03-23 | — | — | CN | disclosed |
| US-7812041-B2 | Heterocyclic NF-κB inhibitors | 4SC AG (DE) | 2010-10-12 | — | — | US | disclosed |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| CN-100360133-C | Tetrodotoxin respiratory tract administration prepn. used for giving-up drug and easing pain | XINFU PAN (CN) | 2008-01-09 | — | — | CN | disclosed |
| CN-101031567-A | Novel heterocyclic NF-kB inhibitors | 4SC AG (DE) | 2007-09-05 | — | — | CN | disclosed |
| EP-1797084-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
| WO-2006032322-A1 | NOVEL HETEROCYCLIC NF-κB INHIBITORS | 4SC AG (DE) | 2006-03-30 | — | — | WO | disclosed |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-03-30 | — | — | US | disclosed |
| CN-1688582-A | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORP (US) | 2005-10-26 | — | — | CN | disclosed |
| EP-1549652-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004029055-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
| CN-1459286-A | Tetrodotoxin respiratory tract administration prepn. used for giving-up drug and easing pain | PAN XINFU (CN) | 2003-12-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | EGFR 352/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | EGFR 468/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, NFKB2, NFRKB | EGFR 131/4885PIK3CD 3724/4885PIK3CA 3274/4885 |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFKB2, NFRKB | EGFR 109/4885PIK3CD 3843/4885PIK3CA 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.